Investor Group Provides $120 Million Private Placement to Bolt Biotherapeutics

Bolt Biotherapeutics Acquires Prana Therapies

October 24, 2026

Biotechnology

Bolt Biotherapeutics acquired Prana Therapies in a stock-for-stock reverse merger. The combination gives Bolt Prana’s INSPIRE multispecific-antibody platform and pipeline, including PRA-216, which Bolt plans to advance through Phase 2 clinical trials.

Boundless Bio and Serapha Bio Announce Merger and $230 Million Private Placement

June 25, 2026

Biotechnology

Boundless Bio and Serapha Bio entered into a definitive agreement to merge in an all-stock transaction. Serapha will combine with Boundless Bio, with the combined company expected to operate as Serapha Bio and trade on Nasdaq under ticker AATD, following a pre-closing $230 million private investment led by RA Capital Management and RTW Investments.

Bain Capital Life Sciences Leads $200M Growth Investment in Serán Bioscience

September 17, 2024

Pharmaceuticals

Bain Capital Life Sciences led a strategic growth investment of more than $200 million in Serán Bioscience, with existing investor Vivo Capital remaining a key shareholder. The capital will fund a new commercial-scale manufacturing campus in Bend, Oregon, expanding Serán's development, analytical and commercial manufacturing capabilities across multiple drug delivery modalities.

Century Therapeutics Acquires Clade Therapeutics; Raises $60M Private Placement Led by Bain Capital Life Sciences

April 11, 2024

Biotechnology

Century Therapeutics agreed to acquire privately held Clade Therapeutics for approximately $35 million in upfront consideration (plus a potential $10 million milestone) to expand its iPSC-derived cell therapy pipeline and next-generation Allo-EvasionTM platform. Concurrently, Century completed a roughly $60 million private placement led by Bain Capital Life Sciences and several institutional investors to support expanded autoimmune development of its lead program CNTY-101 and extend cash runway into 2026.

Bain Capital Invests up to $300M in Cardurion Pharmaceuticals

October 27, 2021

Biotechnology

Cardurion Pharmaceuticals, a clinical‑stage biotechnology company focused on cardiovascular therapeutics, received a private investment of up to $300 million from Bain Capital Life Sciences and Bain Capital Private Equity to advance its PDE9 and CaMKII inhibitor programs and to scale the business. The funding will support a major Phase 2 heart‑failure trial, initiation of first‑in‑human studies, and company growth; Bain Capital will also join Cardurion’s board alongside existing investors Takeda Pharmaceuticals and Polaris Partners.

Capitala Group and Pike Street Capital Invest $19.5M in US BioTek Laboratories

January 8, 2019

Healthcare Services

Capitala Group, alongside Pike Street Capital, provided a $19.5 million financing package (senior secured debt and equity) to US BioTek Laboratories to support the company's next phase of growth. The capital will fund expansion of US BioTek's specialty immunology and allergy testing capabilities as well as sales and marketing initiatives.